Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2
Autor:
Tzou, Philip L.
; Descamps, Diáne
; Rhee, Soo-Yon
; Raugi, Dana N
; Charpentier, Charlotte
; Taveira, Nuno
; Smith, Robert A
; Soriano, Vicente
; Mendoza, Carmen de
; Holmes, Susan
; Gottlieb, Geoffrey S.
; Shafer, Robert W.
Fecha:
06/2020Palabra clave:
Revista / editorial:
Journal of Infectious DiseasesTipo de Ítem:
Articulo Revista IndexadaDirección web:
https://academic.oup.com/jid/article-abstract/221/12/1962/5713448?redirectedFrom=fulltextResumen:
Background: HIV-1 and HIV-2 differ in their antiretroviral (ARV) susceptibilities and drug resistance mutations (DRMs). Methods: We analyzed published HIV-2 pol sequences to identify HIV-2 treatment-selected mutations (TSMs). Mutation prevalences were determined by HIV-2 group and ARV status. Nonpolymorphic mutations were those in <1% of ARV-naive persons. TSMs were those associated with ARV therapy after multiple comparisons adjustment. Results: We analyzed protease (PR) sequences from 483 PR inhibitor (PI)-naive and 232 PI-treated persons; RT sequences from 333 nucleoside RT inhibitor (NRTI)-naive and 252 NRTI-treated persons; and integrase (IN) sequences from 236 IN inhibitor (INSTI)-naive and 60 INSTI-treated persons. In PR, 12 nonpolymorphic TSMs occurred in ≥11 persons: V33I, K45R, V47A, I50V, I54M, T56V, V62A, A73G, I82F, I84V, F85L, L90M. In RT, 9 nonpolymorphic TSMs occurred in ≥10 persons: K40R, A62V, K70R, Y115F, Q151M, M184VI, S215Y. In IN, 11 nonpolymorphic TSMs occurred in ≥4 persons: Q91R, E92AQ, T97A, G140S, Y143G, Q148R, A153G, N155H, H156R, R231 5-amino acid insertions. Nine of 32 nonpolymorphic TSMs were previously unreported. Conclusions: This meta-analysis confirmed the ARV association of previously reported HIV-2 DRMs and identified novel TSMs. Genotypic and phenotypic studies of HIV-2 TSMs will improve approaches to predicting HIV-2 ARV susceptibility and treating HIV-2-infected persons.
Este ítem aparece en la(s) siguiente(s) colección(es)
Estadísticas de uso
Año |
2012 |
2013 |
2014 |
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Vistas |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
49 |
35 |
47 |
40 |
43 |
Descargas |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
Increased incidence of giant cell arteritis and associated stroke during the COVID-19 pandemic in Spain: A nation-wide population study
Moreno-Torres, Víctor; Soriano, Vicente; Calderon-Parra, Jorge; Martinez-Urbistondo, Maria; Treviño, Ana; de San Vicente, Zayrho; de Mendoza, Carmen; Ruiz-Irastorza, Guillermo (Autoimmunity Reviews, 2023)INTRODUCTION: SARS-CoV-2 infection and COVID-19 vaccines might have increased the incidence of giant-cell arteritis (GCA) and the risk of associated stroke in Spain. METHODS: Retrospective nation-wide observational ... -
Impact of scaling up SARS-CoV-2 vaccination on COVID-19 hospitalizations in Spain
Barandalla, Ignacio ; Alvarez, Carmen ; Barreiro, Pablo; de Mendoza, Carmen; González-Crespo, Rubén ; Soriano, Vicente (Elsevier B.V., 2021)Background: The advent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines has been associated with a significant decline in coronavirus disease 2019 (COVID-19) hospitalizations and deaths. However, ... -
Susceptibility to hepatitis B virus infection in adults living in Spain
Soriano, Vicente; Aguilera, Antonio; Benito, Rafael; Gonzalez-Diez, Rocio; Miro, Elisenda; Liendo, Paloma; Rodriguez-Diaz, Juan Carlos; Cabezas, Teresa; Richart, Alberto; Ramos, José Manuel; Barea, Luisa; Alvarez, Carmen; Treviño, Ana; Gómez-Gallego, Felix; Corral, Octavio Jorge; de Mendoza, Carmen (Liver International, 2023)BackgroundA protective hepatitis B virus (HBV) vaccine has been available for four decades. Universal HBV vaccination of infants is recommended by the WHO since the 1990s. Furthermore, HBV immunization is advised for all ...